API | filociclovir

filociclovir Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Filociclovir is an antiviral drug which was developed for the treatment of cytomegalovirus infection and also shows some activity against other double-stranded DNA viruses. It has reached Phase II human clinical trials. ^Wikipedia

Chemistry

SMILES: Nc1nc2c(ncn2/C=C2/CC2(CO)CO)c(=O)[nH]1
InChIKey: KMUNHOKTIVSFRA-KXFIGUGUSA-N
Mol. Mass: 263.26
ALogP: -1.08 Partition coefficient
ChEMBL Molecule:
filociclovir

More Chemistry

Pharmacology

Mechanisms of Action:
- DNA polymerase (Human cytomegalovirus) ^UniProt
- Serine/threonine protein kinase UL97 (Human cytomegalovirus (strain AD169) (HHV-5) (Human herpesvirus 5)) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Cytomegalovirus Infections (Phase 1)

Healthy Volunteers (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 2
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue